Literature DB >> 26590771

Recent developments in HLA-haploidentical transplantations.

Margaret Showel1, Ephraim J Fuchs2.   

Abstract

While allogeneic hematopoietic stem cell transplantations have a curative potential, several patients with hematologic malignancies cannot avail themselves of this therapeutic option due to lack of matched donor availability. Although HLA-haploidentical transplantations were previously associated with poor outcomes, recent evidence with use of post transplantation cyclophosphamide indicate improved safety and efficacy. The following paper discusses the most recent developments in this area.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Cyclophosphamide; Graft versus host disease; HLA-haploidentical transplantation; Matched related donor; Matched unrelated donor; Mismatched unrelated donor; Relapse

Mesh：

Substances：

Year:  2015        PMID： 26590771      PMCID： PMC5013658          DOI： 10.1016/j.beha.2015.10.011

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  14 in total

1.  Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Jennifer A Kanakry; Margaret M Showel; Hua-Ling Tsai; Javier Bolaños-Meade; Gary L Rosner; Christopher G Kanakry; Karlo Perica; Heather J Symons; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; Keith W Pratz; Gabrielle T Prince; Amy E Dezern; Ivana Gojo; William H Matsui; Ivan Borrello; Michael A McDevitt; Lode J Swinnen; B Douglas Smith; Mark J Levis; Richard F Ambinder; Leo Luznik; Richard J Jones; Ephraim J Fuchs; Yvette L Kasamon
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

Review 2.  HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.

Authors:  E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

3.  A disease risk index for patients undergoing allogeneic stem cell transplantation.

Authors:  Philippe Armand; Christopher J Gibson; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Jerome Ritz; Mohamed L Sorror; Stephanie J Lee; H Joachim Deeg; Barry E Storer; Frederick R Appelbaum; Joseph H Antin; Robert J Soiffer; Haesook T Kim
Journal:  Blood       Date:  2012-06-18       Impact factor: 22.113

4.  Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.

Authors:  C Anasetti; P G Beatty; R Storb; P J Martin; M Mori; J E Sanders; E D Thomas; J A Hansen
Journal:  Hum Immunol       Date:  1990-10       Impact factor: 2.850

5.  Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.

Authors:  R Szydlo; J M Goldman; J P Klein; R P Gale; R C Ash; F H Bach; B A Bradley; J T Casper; N Flomenberg; J L Gajewski; E Gluckman; P J Henslee-Downey; J M Hows; N Jacobsen; H J Kolb; B Lowenberg; T Masaoka; P A Rowlings; P M Sondel; D W van Bekkum; J J van Rood; M R Vowels; M J Zhang; M M Horowitz
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

6.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

Authors:  Asad Bashey; Xu Zhang; Connie A Sizemore; Karen Manion; Stacey Brown; H Kent Holland; Lawrence E Morris; Scott R Solomon
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

7.  Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Brent R Logan; Zhiwei Wang; Edwin P Alyea; Matt E Kalaycio; Richard T Maziarz; Joseph H Antin; Robert J Soiffer; Daniel J Weisdorf; J Douglas Rizzo; Mary M Horowitz; Wael Saber
Journal:  Blood       Date:  2014-04-17       Impact factor: 22.113

8.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.

Authors:  F Aversa; A Tabilio; A Velardi; I Cunningham; A Terenzi; F Falzetti; L Ruggeri; G Barbabietola; C Aristei; P Latini; Y Reisner; M F Martelli
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

9.  Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion.

Authors:  R C Ash; M M Horowitz; R P Gale; D W van Bekkum; J T Casper; E C Gordon-Smith; P J Henslee; H J Kolb; B Lowenberg; T Masaoka
Journal:  Bone Marrow Transplant       Date:  1991-06       Impact factor: 5.483

10.  Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.

Authors:  Christopher G Kanakry; Sudipto Ganguly; Marianna Zahurak; Javier Bolaños-Meade; Christopher Thoburn; Brandy Perkins; Ephraim J Fuchs; Richard J Jones; Allan D Hess; Leo Luznik
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956
View more
  1 in total

1.  Complete resolution of severe ulcerative colitis after haploidentical hematopoietic stem cell transplantation followed by post-transplant high-dose cyclophosphamide.

Authors:  A Unnikrishnan; S C Glover; O Norkina; J R Wingard; M Norkin
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.